Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
暂无分享,去创建一个
P. Greenberg | A. Raza | J. Holland | F. Wilhelm | M. Maniar | L. Silverman | M. Olnes | P. Reddy
[1] M. Voso,et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Bennett,et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial , 2013, Haematologica.
[3] J. Vardiman. The classification of MDS: from FAB to WHO and beyond. , 2012, Leukemia research.
[4] M. Laouri,et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need , 2012, Transfusion.
[5] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[6] M. Konopleva,et al. Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients , 2012, Cancer.
[7] N. Young,et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. , 2012, Leukemia research.
[8] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Felsher,et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. , 2010, Leukemia research.
[10] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Reddy,et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. , 2011, Journal of medicinal chemistry.
[12] J. Maciejewski,et al. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia , 2011, Cancer.
[13] J. Issa,et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.
[14] P. Fenaux,et al. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. , 2009, Leukemia research.
[15] P. Greenberg,et al. Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound. , 2009 .
[16] S. Cosenza,et al. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent , 2009, Cancer Chemotherapy and Pharmacology.
[17] E. Reddy,et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells , 2009, Oncogene.
[18] H. Kantarjian,et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. , 2008, Journal of the National Cancer Institute.
[19] T. Haferlach,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.
[20] J. Issa,et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome , 2007, Cancer.
[21] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[22] Kiranmai Gumireddy,et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. , 2005, Cancer cell.
[23] P. Fenaux. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. , 2004, Seminars in hematology.
[24] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[25] W. Hiddemann,et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. , 2003, Blood.
[26] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.